We are one of the largest preclinical contract research organizations in Europe, driven by a clear mission:
to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.
Chief Executive Officer
Boguslaw Sieczkowski is a co-founder of Selvita and currently holds the position of the Chief Executive Officer. Mr. Sieczkowski has over 17 years of experience in management within the field of high-tech companies. His managerial experience includes roles at Bahlsen Group, Board Member at Comarch Internet Ventures S.A., Vice President at Comarch S.A., and most recently Chief Operating Officer and Executive Vice President at Selvita Group responsible for the full operational management of the Company.
In 2013, Mr. Sieczkowski was awarded Knight’s Cross of the Order of Polonia Restituta for his contributions to the development of Poland’s business environment. He holds MBA title from joint programme of the University of Teesside (United Kingdom) and Krakow School of Economics (Poland), M.Sc. degree from Jagiellonian University in Krakow as well as Project Management Professional certificate issued by Project Management Institute (United States).
Chief Commercial Officer, Executive Vice President
Dr. Milosz Gruca is the Executive Vice President and Chief Commercial Officer at Selvita Group, responsible for a broad scope of business development activities of the Company, including creation and development of drug discovery and regulatory services’ offer, building relationships with international clients, as well as operational management of the integrated Business Development Department.
Dr. Gruca has been with Selvita since 2007. As the Director of Biology, he was responsible for introducing comprehensive biological and analytical services to the company’s offer and subsequently strategic management of the Analytical, Biochemistry, and Molecular Biology Departments.
Dr. Milosz Gruca is a graduate of the Jagiellonian University, where he earned his M.Sc.in Biotechnology and Ph.D. in Biochemistry. He also holds an Executive MBA from the joint program at Stockholm University School of Business and the Krakow University of Economics Business School.
Chief Operating Officer
Miroslawa Zydron, Ph.D., Eng., MBA joined Selvita in 2009, and since then has been responsible for the organization, and dynamic growth of the Chemistry Department, strategic development of chemistry offer within drug discovery and drug development fields, overseeing the ongoing projects to ensure the highest quality of results, as well as presentation of the company’s portfolio of services and building relationships with partners from the pharmaceutical, biotechnology, chemical and agrochemical environments, globally.
In February 2022, Dr. Zydron has taken the position of Chief Operating Officer. The key responsibility of Dr. Zydron as the Selvita Group’s Chief Operating Officer is to support its further dynamic growth and manage the growing scale of operations, along with effectiveness in the delivered projects, through continuous improvement of the organization, processes, and business tools, as well as investment into and development of the state-of-the-art infrastructure and technologies.
Before joining Selvita, Dr. Miroslawa Zydron had worked within Pliva R&D structures (then Barr Pharmaceuticals), as a Laboratory Manager, overseeing analytical and preformulation activities at the stage of drug form development and packaging processes in pilot production in the GMP environment, as well as a Project Manager responsible for leading optimization projects in the Production and Quality Departments (TEVA).
Dr. Zydron graduated from the Silesian Technical University (Poland), with M.Sc. Eng. in Chemistry and Ph.D. in Analytical Chemistry (with honors). She also holds MBA title from the Rotterdam School of Management at Erasmus University in Rotterdam (Netherlands).
Global Head of Drug Discovery, Member of the Management Board
Dr. Adrijana Vinter has held the position of Managing Director at Fidelta, now part of Selvita Group, since 2017. In February 2022, Dr. Vinter has taken the position of Global Head of Drug Discovery, and been appointed to Selvita Management Board.
As the Global Head of Drug Discovery, she is in charge of Selvita Group’s Drug Discovery Segment, responsible for the strategic development of the drug discovery services offer, as well as leadership of interdisciplinary teams of researchers and overseeing of the ongoing projects to ensure the highest quality of services.
Dr. Vinter started her career in PLIVA in 2002, initially working as a scientist in the medicinal chemistry field. Following foundation of Fidelta, she moved to Business Development, which she was heading until 2017, when she took the position of Managing Director and President of the Management Board. As the Managing Director, Dr. Vinter was responsible for Fidelta’s full operational management and has successfully engineered and overseen the development of its revenue stream, resulting in significant year-on-year growth.
Dr. Vinter obtained her Ph.D. in Organic Chemistry at the University of Zagreb in the field of new macrolide antibiotics. She also holds an MBA title from Cotrugli Business School, Croatia. Dr. Vinter is the author of several scientific publications.
General Counsel, Member of the Management Board
Dawid Radziszewski has joined Selvita in 2015 taking the position of an in-house lawyer overseeing company’s legal affairs. Since then he has been promoted to the position of General Counsel, and entrusted with an assignment to build and manage a company’s legal department. He is in charge of all legal matters, including in particular complex corporate issues, IP licensing transactions, as well as a corporate development of the Company. As a Management Board Member, he is additionally responsible for Selvita’s activity in the field of mergers and acquisitions.
Prior to joining Selvita, Dawid Radziszewski has gained several years of experience at one of the leading law firms WKB Wierciński, Kwieciński, Baehr, working in area of corporate law and M&A. Previous to that he was affiliated with the Allerhand Institute – an independent research centre, which conducts interdisciplinary and comparative studies on the role of legal institutions in economic markets. Laureate of the contest “Rising Stars – lawyers, leaders of tomorrow”, in 2018. Dawid Radziszewski is an advocate, a graduate of the Jagiellonian University and Heidelberg University where he earned his LL.M title. He has also studied at the University of Zurich.
Chief Financial Officer
Dariusz Kurdas joined Selvita in August 2019, taking the position of Chief Financial Officer, and assuming the responsibility for financial activities at Selvita.
Prior to joining Selvita, Dariusz spent several years at KPMG Audyt managing an audit team. He also held accounting and financial positions at Nowy Styl, Polish-based European leader in comprehensive office solutions with local structures in many countries around the world, where while executing financial controller responsibilities he was responsible for financial, accountancy and controlling support, budgets’ forecasting and control, as well as control of fulfilment of bank covenants of subsidiaries in Germany. In 2016, he joined Liugong Dressta Machinery where he held the position of Finance Director and subsequently, Chief Financial Officer, managing accounting, finance and controlling teams.
Dariusz Kurdas graduated in Finance from Krakow University of Economics and Tilburg University (the Netherlands). He is a registered Public Certified Auditor and licensed stockbroker.
Chairman of the Supervisory Board
Dr. Romanowski is a senior advisor and investor across biotech, deep tech and financial services. He is the Chairman of the Supervisory Board of Ryvu Therapeutics S.A. Previously, Dr. Romanowski has spent over 20 years in strategic management consulting as Partner in McKinsey & Company and PwC where he specialized in strategy and M&A in financial services, oil & gas, pharmaceuticals, and health care.
Dr. Romanowski was also a Board Member at Bank Millennium S.A. responsible for Corporate and Investment Banking. He holds a Ph.D. in molecular biology from the University of Cambridge and MD, Ph.D. in cancer genetics from the Medical University of Gdańsk. Dr. Romanowski is a Member of the Audit Committee at Selvita.
Vice Chairman of the Supervisory Board
Dr. Tadeusz Wesolowski received his PhD in Technical Sciences from Warsaw University of Technology. After receiving his diploma, he worked at the university as a lecturer. In 1990, he established and managed PROSPER company (part of NEUCA Group). Dr. Wesolowski consistently advised and participated in the creation of new ventures in the pharmaceutical market. Dr. Wesołowski is a Member of the Audit Committee at Selvita.
Supervisory Board Member
Pawel Przewiezlikowski is currently Chief Executive Officer of Ryvu Therapeutics, biotechnology company developing innovative therapies that address clinical limitations of current treatments in oncology, which was founded upon the split of Selvita oncology development and research services divisions into separate companies. Przewiezlikowski is also the co-founder and former CEO of Selvita, who oversaw strategic management, business and corporate development of Selvita Group for over 12 years. He is also the President of the Board at Ardigen. Przewiezlikowski was a member of the executive team at Comarch technology company. He was also the co-founder of Interia.pl, Poland’s third largest internet portal. Mr. Przewięźlikowski holds an MBA from the Teesside University (UK) and Cracow University of Economics. He also holds a master degree in computer science from AGH Technical University in Krakow and studied IT at the Technical University in Berlin.
Supervisory Board Member
Mr. Rafal Chwast is a graduate of Cracow University of Economics (Accounting) and the AGH Technical University in Krakow (Computer Science). From 1997-2007, he served as Vice President and Chief Financial Officer at Comarch. He was responsible for financial supervision of group’s subsidaries, raising capital through the stock exchange for Comarch and Interia.pl, and the acquisition of the CDN company. From 2003-2006, he served as CEO of the Association of Stock Exchange Issuers, and was also a member of the Capital Market Council operating at the Prime Minister. Mr. Chwast is the President of the Audit Committee at Selvita.
Supervisory Board Member
Mr. Wojciech Chabasiewicz graduated from the Faculty of Law and Administration of Jagiellonian University and was entered on the list of Legal Counsels in 2005. Mr. Chabasiewicz specializes in corporate law, capital markets and securities, mergers and acquisitions, as well as in issues related to bankruptcy and restructuring. Between 2005 and 2009, he was a Partner at the law firm Tomasik, Chabasiewicz & Partners LP. He is currently a partner at the Chabasiewicz, Kowalska and Partners LP. Since the very beginning of his professional career, Mr. Chabasiewicz has been advising on the public and private stock and bond issues, mergers and acquisitions and restructuring transactions. He also deals with all types of investigations related to corporate conflicts. Additionally, Mr. Chabasiewicz is a Member of the Audit Committee at Selvita.
Supervisory Board Member
Jacek Osowski is an investment adviser and auditor with ample experience in building investement strategies and overseeing equity transactions. From 2007–2008, he was the Vice President of the Management Board of IPOPEMA TFI S.A., Subsequently, he worked as the Deputy Director of the Treasurer’s Office at PZU S.A./PZU Życie S.A. (2008-2009). From 2009-2011, he was the Vice President of the Management Board, CIO, Director at PZU Asset Management S.A. Moreover, he was Famur S.A. management board member. Jacek Osowski is a graduate of the Warsaw School of Economics (banking and finance). He obtained an MBA degree at the University of Warsaw and the University of Illinois (2005-2006). Furthermore, Jacek Osowski holds investment adviser license and Chartered Financial Accountant (CFA) license. He is also on the list of statutory auditors.